Acute lymphoblastic leukemia in children: A short review

Document Type : Review Article


1 Department of Clinical Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran


Acute lymphoblastic leukemia is as the most common childhood cancer. The definite etiology of childhood ALL is unknown. The pathogenesis of ALL is described as the disruption of lymphocyte proliferation and differentiation. The most common signs and symptoms of ALL are fever, hepatosplenomegaly, lymphadenopathy, pallor, and bleeding. Diagnosis is based on conducting complete blood cell, peripheral blood smear, bone marrow aspirate, immunophenotype, and cytogenetics tests. A number of demographic, clinical, and paraclinical characteristics of patients have been determined as prognostic factors. To select the appropriate treatment protocol, patients are risk stratified. In induction therapy, vincristine, corticosteroid, and asparaginase are given for the low- and standard risk groups and a four-drug induction therapy including vincristine, corticosteroid, asparaginase, and anthracycline are given for high- and very high-risk group for B cell ALL. The induction phase follow with post-induction courses including consolidation, interim maintenance, delayed intensification, and maintenance phases. ALL in pediatrics has a good prognosis and high cure rate.


1. Lanzkowsky P, Lipton JM, Fish JD. Lanskowsky's manual of pediatric hematology and oncology. 6th ed. London: Elsevier Science; 2016.
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-43.
3. Zeind CS, Carvalho GM. Pediatric malignancies. In: Henry DW, Kaiser NA, editors. Applied therapeutics : the clinical use of drugs. 11th ed. Philadelphia: Wolters Kluwer; 2018.
4. Farahmand M, Almasi-Hashiani A, Hassanzade J, Moghadami M. Childhood cancer epidemiology based on cancer registry's data of Fars province of Iran. Koomesh. 2011;13(1):8-13 [In Persian].
5. Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma. Leuk Lymphoma. 2013 Sep;54(9):2035-40. doi: 10.3109/10428194.2013.769218. Epub 2013 Feb 28. PMID: 23363221.
6. Bruwier A, Chantrain CF. Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr. 2012 Sep;171(9):1301-7. doi: 10.1007/s00431-011-1624-1. Epub 2011 Nov 24. PMID: 22113227.
7. Mrózek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct;23(5):991-1010, v. doi: 10.1016/j.hoc.2009.07.001. PMID: 19825449; PMCID: PMC3607311.
8. Hakeem A, Shiekh AA, Bhat GM, Lone AR. Prognostification of ALL by Cytogenetics. Indian J Hematol Blood Transfus. 2015;31(3):322-331. doi:10.1007/s12288-014-0483-0
9. Jastaniah W, Elimam N, Abdalla K, AlAzmi AA, Aseeri M, Felimban S. High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia. Leuk Res Rep. 2018;10:44-51. Published 2018 Oct 9. doi:10.1016/j.lrr.2018.10.001
10. Biggs JR, Zhang DE. Molecular basis of lymphoid and myeloid diseases. In: Coleman WB, Tsongalis GJ, editors. Molecular pathology: the molecular basis of human disease. 2 ed. London: Elsevier Science 2018. p. 299-328.
11. Naeim F, Rao N, Song SX, Grody WW. Lymphocytopenia and lymphocytosis. In: F. N, editor. Atlas of hematopathology: morphology, immunophenotype, cytogenetics, and molecular approaches. London: Academic Press; 2013. p. 627-33.
12. Tadmor T, Polliack A. Lymphopenia a simple prognostic factor in lymphoma and other cancers: why not use it more as a guide? Leuk Lymphoma. 2010 Oct;51(10):1773-4. doi: 10.3109/10428194.2010.508825. PMID: 20849382.
13. Rubnitz JE, Campbell P, Zhou Y, Sandlund JT, Jeha S, Ribeiro RC, Inaba H, Bhojwani D, Relling MV, Howard SC, Campana D, Pui CH. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer. 2013 Jun 1;119(11):2061-6. doi: 10.1002/cncr.28026. Epub 2013 Mar 1. PMID: 23456849; PMCID: PMC3862024.
14. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011 Jan;22(1):149-155. doi: 10.1093/annonc/mdq314. PMID: 20595450.
15. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer. 2008 Jan 15;112(2):407-15. doi: 10.1002/cncr.23168. PMID: 18058809.
16. Le Jeune C, Bertoli S, Elhamri M, Vergez F, Borel C, Huguet F, et al. Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leuk Lymphoma. 2014 Apr;55(4):855-62. doi: 10.3109/10428194.2013.813504. Epub 2013 Aug 5. PMID: 23786457.
17. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007 Feb 1;109(3):926-35. doi: 10.1182/blood-2006-01-024729. Epub 2006 Sep 26. PMID: 17003380; PMCID: PMC1785141.
18. Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012 Jul;97(7):1048-56. doi: 10.3324/haematol.2011.047613. Epub 2012 Jan 22. PMID: 22271901; PMCID: PMC3396677.
19. Society AC. Prognostic Factors in Childhood Leukemia (ALL or AML) 2020 [Available from:
20. Whitehead VM, Vuchich MJ, Cooley LD, Lauer SJ, Mahoney DH, Shuster JJ, et al. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Leuk Lymphoma. 1998 Nov;31(5-6):507-19. doi: 10.3109/10428199809057610. PMID: 9922041.
21. Raimondi SC, Pui CH, Hancock ML, Behm FG, Filatov L, Rivera GK. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia. 1996 Feb;10(2):213-24. PMID: 8637229.
22. Whitehead VM, Payment C, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, et al. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 2001 Jul;15(7):1081-8. doi: 10.1038/sj.leu.2402165. PMID: 11455977.
23. Wojtuszkiewicz A, Peters GJ, van Woerden NL, Dubbelman B, Escherich G, Schmiegelow K, et al. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. J Hematol Oncol. 2015 May 29;8:61. doi: 10.1186/s13045-015-0158-9. PMID: 26022503; PMCID: PMC4455979.
24. Wells BG, L. ST, DiPiro JT, DiPiro CV. oncologic disorders. Pharmacotherpay handbook. 10th ed. New York: McGraw-Hill Education; 2017.
25. Amir AH, Soheil Z, Mehran K, Esmaeil K, Abolfazl M. Survival rate of childhood leukemia in shiraz, southern iran. Iran J Pediatr. 2013 Feb;23(1):53-8. PMID: 23550191; PMCID: PMC3574992.
26. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Jan;18(1):81-112. doi: 10.6004/jnccn.2020.0001. PMID: 31910389.
27. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020 Nov 1;105(11):2524-39. doi: 10.3324/haematol.2020.247031. PMID: 33054110; PMCID: PMC7604619.
28. Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PMID: 32247396.
29. Tran TH, Loh ML. Ph-like acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):561-566. doi:10.1182/asheducation-2016.1.561